A5024235134- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Pharmaceutical Practices and Patient Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- BRCA gene mutations in cancer
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Statistical Methods in Clinical Trials
- Pharmaceutical studies and practices
- Medication Adherence and Compliance
- Mobile Health and mHealth Applications
- Lipoproteins and Cardiovascular Health
- Acute Lymphoblastic Leukemia research
- Platelet Disorders and Treatments
- Polyomavirus and related diseases
- Cancer Genomics and Diagnostics
- Nutrition, Genetics, and Disease
- Ethics in Clinical Research
- Biosimilars and Bioanalytical Methods
- Cancer Treatment and Pharmacology
- Renal Transplantation Outcomes and Treatments
- Innovations in Medical Education
- Health and Medical Research Impacts
- PI3K/AKT/mTOR signaling in cancer
Humana (United States)
2019-2023
Pharmaceutical Research and Manufacturers of America
2021
University of Pennsylvania
2021
Otsuka (United States)
2021
Sage Therapeutics (United States)
2021
Regeneron (United States)
2021
Janssen (Switzerland)
2021
General Department of Preventive Medicine
2021
Sanofi (France)
2021
AbbVie (United States)
2021
Abstract Background Overall response rates ( ORR s) for ipilimumab in advanced melanoma are only about 10%. Hence, it is important to explore biomarkers predicting responders. Objective We aimed predict therapy outcome patients who have undergone standard a real‐world setting. Methods Databases of cutaneous n = 52) had received were reviewed and data collected on patient characteristics diverse laboratory parameters. performed univariate multivariate statistics including logistic regression...
BACKGROUND: Few studies have examined oral anticancer treatment utilization patterns among Medicare beneficiaries. OBJECTIVE: To assess of newly initiated agents across national samples beneficiaries for 5 cancer types: chronic myeloid leukemia (CML), multiple myeloma (MM), metastatic prostate (mPC), renal cell carcinoma (mRCC), and breast (mBC). METHODS: This retrospective claims analysis used 100% Chronic Condition Data Warehouse (CCW) Parts A, B, D files from 2011 to 2014 (for CML, MM,...
Objective The purpose of this study was to identify trends in oncology care that allow one forecast workforce supply and demand, the training skills needed by pharmacist for likely future care. Methods Interviews were conducted with experienced pharmacists leadership roles at 20 organizations balanced geographic region type practice site (academic or community/ambulatory). Results analyzed using descriptive statistics theme identification. Practice sites differed widely numbers patient...
We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs.irAEs were defined using medical pharmacy claims enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment anti-PD(L)-1 received ≥ 1 dose therapy between September 2014 28 February 2018.Treatment was discontinued 46.6% patients, withheld subsequently restarted 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index higher irAEs.These data underscore...
Purpose Patients with head and neck cancer are at risk for disease- treatment-related toxicities that may be severe enough to require hospitalization. The factors associated hospitalization in these patients not well defined. Methods We conducted a single-center, retrospective observational study of receiving chemotherapy an academic medical center infusion clinic one-year period. primary objective was characterize the population center. Secondary objectives included describing clinical...
The primary objective was to analyze the initial tacrolimus concentrations achieved in allogeneic hematopoietic stem cell transplantation patients using institutional dosing strategy of 1 mg IV daily initiated on day +5. secondary objectives were ascertain dose, days therapy, and dose changes necessary achieve a therapeutic concentration, identify patient-specific factors that influence dose. relationships between number pre-therapeutic incidence graft-versus-host disease graft failure...
PURPOSE To develop an approach to identify and evaluate recent use of multigene panel testing over time. METHODS We conducted a retrospective database analysis using medical pharmacy claims data. Medicare Advantage Prescription Drug Plan members diagnosed with select malignant solid tumors were identified. The pattern somatic genetic for each patient was evaluated from January 2016 through December 2018. Tests classified by the number genes tested in panel: < 50 (small or medium) ≥...
The development, structure, and implementation of an innovative residency program designed to help meet a growing need for pharmacists with specialized expertise in investigational drug use clinical research are described.Clinical has become increasingly complex field, but prior 2017 there were no U.S. specialty training programs focused on pharmacists' role development the care patients enrolled trials. In 2016 Johns Hopkins Hospital (JHH) launched initiative develop standards specific...
Busulfan has a narrow therapeutic index, making dosing in obesity dilemma. The busulfan pharmacokinetic (PK) profile is related to many variables including body size. By normalizing size, variability clearance reduced. difficulty the selection of an appropriate measure size for normalization. objectives this study were determine if dosed on ideal weight (IBW) overweight patients (BMI ≥ 25 kg/m2) leads differences PK parameter area under concentration-versus-time curve (AUC) first dose and...
Background: The evaluation and implementation of tailored outpatient pharmacy services for patients undergoing hematopoietic stem cell transplantation (HCT) in a unique clinic comprehensive cancer center are described. Summary: Supportive medications used HCT crucial preventing HCT-related complications. High prescription costs complex medication regimens contribute to decreased adherence. In this center, the majority HCTs performed completely oral must be obtained from an pharmacy....
Background: Anti-PD1/PD-L1 therapy is standard-of-care for patients with a variety of advanced malignancies. Although clinical trials report lower incidence grade 3-4 toxicities than observed cytotoxic agents, it imperative that clinicians identify and manage the unique these agents. We aimed to real-world immune-related management treated anti-PD1/PD-L1 agents prior publication practice guidelines. Methods: Patients enrolled in Humana Medicare Advantage plan who initiated any September 1,...